ABSTRACT: A fundamental question is how to detect likely successful anticancer treatments based on nanotechnology. We confront this question here by analysing the trajectories of nanotechnologies applied to path-breaking cancer treatments, which endeavour to pinpoint ground-breaking and fruitful directions in nanomedicine. Results tend to show two main technological waves of cancer treatments by nanotechnology applications. The early technological wave in the early 2000s was embodied in some types of chemotherapy agents with a broad spectrum, while after 2006 the second technological wave appeared with new nanotechnological applications in both chemotherapy agents and molecular target therapy. The present study shows new directions of nanotechnology-based chemotherapy and molecular cancer therapy in new treatments for breast, lung, brain and colon cancers. A main finding of this study is the recognition that, since the late 2000s, the sharp increase of several technological trajectories of nanotechnologies and anticancer drugs seems to be driven by high rates of mortality of some types of cancers (e.g. pancreatic and brain) in order to find more effective anticancer therapies that increase the survival of patients. The study also shows that global research leaders specialize in nanotechnology applications for specific cancers (e.g. Switzerland in prostate cancer, Japan in colon cancer, China in ovarian cancer and Greece in pancreatic cancer). These ground-breaking technological trajectories are paving new directions in biomedicine and generating a revolution in clinical practice that may lead to more effective anticancer treatments in the not-too-distant future.
Introduction and the problem
Interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life sciences support the diagnosis, monitoring, prevention and treatment of diseases. Nanotechnology in medicine has generated a vital technological change and as a consequence a revolution in clinical practice. (Islam and Miyazaki, 2010; Rafols and Meyer, 2010; Coccia, 2012a; Wolinsky et al., 2012; Madeira et al., 2013) 2 . No and Park (2010) , using patent citations, argue that the interaction of biotechnology and nanotechnology may provide important signals for future patterns in nanobiomedicine (cf. Sylvester and Bowman, 2010; Coccia, 2012) . In fact, nanotechnology has a high development potential for biomedical purposes such as the ground-breaking applications in new therapies for oncology (cf. Lim et al., 2010; Coccia, 2012a; 2012b) .
Bibliometrics is an important approach for investigating emerging fields of nanotechnology (Arora et al., 2013) . In fact, some studies, based on publications, show that the patterns of nanotechnology research are spreading among different scientific domains and pathways, generating new technological paradigms mainly in chemistry, medicine and engineering research fields (cf. Coccia, 2012a; Robinson et al., 2013) . As far as the performance in nanotechnology research is concerned, Shapira and Wang (2010) show the leadership of some countries, such as the USA and China, which are considered among the top nanotechnology research publishing countries. This result can be due to high R&D investments in this vital research field and incentives given to researchers to publish in Web of Science indexed journals (Lin and Zhang, 2007; Shapira and Wang, 2009 ). However, Youtie et al. (2008) claim that publication counts do not necessarily equate to publication influence.
An interesting problem that deserves to be analysed is how to detect the path-breaking directions of nanotechnology trajectories applied for vital anticancer treatments. In particular, we confront this main issue by analysing:
 the directions of technological trajectories of the most common anticancer drugs (chemotherapy agents, substances, or target therapies) inserted in nanoparticle to treat cancers more effectively;
 the evolutionary pathways of types of cancer where there is a high intensive research activity of treatments that use nanotechnology;  the countries that are best performers in applications of nanotechnologies to treat cancer and the specialization of countries to treat specific cancer by nanotechnology.
This study can provide important information concerning emerging and fruitful directions of nanotechnology applied in ground-breaking anticancer treatments that may generate a revolution in clinical practice to improve human health and quality of life in a nottoo-distant future.
Theoretical background and related works
Breakthroughs in nanotechnology are providing "a new dimension" to medicine (da Rocha et al., 2014) . Therapies integrated in nanoparticles or cooperative nanosystems are spurring new insights to ground-breaking cancer treatments. The National Cancer Institute's nanotechnology strategy started in 2004 to support multidisciplinary researchers in the applications of nanotechnology to new anticancer treatments (Hull et al., 2013) . In fact, R&D in this field has experienced an exponential growth since the early 2000s, such that "cancer nanotherapeutics are progressing at a steady rate" (Bertrand et al., 2013) . For this reason, pharmaceutical companies have formed strategic alliances and partnerships with biotechnology firms to improve and accelerate the drug discovery process (Coccia, 2014a) . A fundamental question in the field of the economics of innovation is how trajectories of scientific fields evolve, expand, converge (or diverge) and break out. Bibliometrics plays a main role to detect and map this continuous evolution (Huang et al., 2014) , being associated with powerful software to analyse diverse and large volume of data. Eisler (2011, p. 1174) consider bibliometrics the "primary method of gaging progress in nanotechnology". As a matter of fact, social scientists, more and more, use bibliometric and scientometric approaches to detect and analyse trajectories in the wide domain of cancer nanotechnology research (Wang et al., 2013) . These approaches play an important role to explore the current evolutionary knowledge growth of trajectories of nanotechnology that may support future patterns of technological innovation in emerging and cutting-edge areas of biomedical sciences. De Bellis (2009) observes that citation analysis, a bibliometric technique, is a prominent feature in the study of new scientific knowledge. Thomas et al. (2011) discuss a nanoparticle ontology for cancer nanotechnology research to represent knowledge underlying nanomaterials involved in cancer research. Huang et al. (2010) show that there are different search strategies for nanotechnology research such as citation analyses, core journal strategies (core is when the journal has nano in its title), lexical queries, etc. (cf. Mogoutov and Kahane, 2007) . Zitt et al. (2011) argue that keywords act as main signals of scientific inquiry, while citations are more effective in identifying research streams. Using a keyword mining approach, Wang et al. (2013) find that the general trend of integration in the application of nanotechnology fields is converging. Arora et al. (2013) employ structured text-mining software to profile keyword terms and identify new nanotechnology-related keywords. This strategy shows the main role of several emerging cited-subject categories of nanotechnology, particularly in the biomedical sciences.
Instead, Zitt and Bassecoulard (2006) employ citation networks to expand their corpus of nanotechnology publications. Leydesdorff and Zhou (2007) present an approach based on a core set of six nanotechnology journals and citation and network analysis to provide fruitful results in understanding this research field.
Among all the research areas, biomedicine is one of the key scientific fields where nanotechnologies are providing vital innovative applications in diagnostics and in therapeutics (Cf. Hu et al., 2011; da Rocha et al., 2014; Gao et al., 2013) . Coccia (2012a) displays that the current convergence of genetics, genomics and nanotechnology is the scientific backbones of new technological paradigms and trajectories in biomedical sciences.
This convergence of vital scientific fields is supporting innovative anticancer treatments and a revolution in clinical practice.
There are several nanotechnologies applied in biomedicine for supporting anticancer treatments (Chen et al., 2011; He et al. 2010; Luo et al., 2011) . For instance, Nanoparticles (NPs) can be designed to selectively target the specific tissue/organ in which there is the cancer (Coccia, 2012b) . In addition, functionalizing the surface of NPs with specific and appropriate ligands can allow their use as drug carriers to target them selectively to the tissue/organ affected by cancer (see Pöselt et al., 2012; Shukoor et al., 2012; Shukoor et al., 2011) . Nanoparticles can also act as carriers for drugs, which can be contained into organic nanomicelles or porous inorganic nanoparticles that, by apt bioactive systems, can target tumoral cells of the body (see Yao et al., 2011; Goel et al., 2010) .
Quantum Dots (QDs), instead, are a specific subset of NPs (Obonyo et al., 2010; Byers and Hitchman, 2011; Rosenthal et al., 2011) . The QDs in medicine are mainly applied as targeted drug delivery (Jain, 2012) .
Carbon nanotubes are an allotropic form of carbon, having cylindrical structure and can be used to deliver drugs against cancer cells, protecting them towards external agents (Ezzati Nazhad Dolatabadi et al., 2011; Bareket et al., 2010) . In fact, carbon nanotubes combined with cytotoxic (antineoplastic or chemotherapy) agents are a key area of development for biomedical sciences (Shapira et al., 2011) . still at the stage of first experimental trials, such as the combination between nanoparticle and siRNA 3 . Gao et al. (2013) show that nanomedicine, based on a targeted drug delivery system, significantly improve cancer metastasis treatments. Hence, nanotechnology-based approaches are a promising research field for early-stage diagnosis and for advanced treatments of cancers that have high rate of mortality (Patra and Truner, 2014; Coccia 2014; Coccia, 2013; 2012c) . GLOBOCAN (2008) shows high mortality (in terms of Age-standardized rate 4 ), in comparison to incidence, by cancer of the lung and bronchus (19.3), breast (12.4), colorectum (8.2), cervix uteri (7.8), prostate (7.4), ovary (3.8), pancreas (3.7) and brain (2.5).
In general, these serious diseases can be treated with: We confront the initial problems of the paper by analysing the evolution and fruitful directions of trajectories of the nanotechnology applied to improve these different types of treatments for above-mentioned cancers with higher rate of mortality.
Method of research
We analyse evolution and direction of the most important and ground-breaking anticancer treatments based on:
 Nanotechnology with chemotherapy agents (cytotoxic anti-neoplastic drugs) such as Paclitaxel, Cisplatin, Gemcitabine, Carboplatin, Docetaxel, Doxorubicin, etc.;
 Nanotechnology with molecular cancer therapies such as herceptin, cetuximab, lapatinib, tamoxifen (anti-oestrogen), and cancer si-RNA therapy;
 Nanotechnology with chemoprevention substances such as curcumin.
Considering the high mortality of some types of cancer discussed in the previous section, seven cancer fields -brain cancer, breast cancer, colon cancer, lung cancer, ovarian cancer, pancreatic cancer and prostate cancer -are covered in our analysis.
The performance of this paper is based on a set of publication and citation data , which also provide substantial information about ground-breaking applications of cancer treatments via nanotechnology, are included while gathering our publication database. However, due to the fact that they do not represent anticancer drugs, they are not illustrated in the technologyspecific analysis.
The study is conducted by the following steps:

Step 1: To examine the evolutionary growth of nanotechnology applied in cancer research. From the perspective of target fields, the evolutionary development of nanotechnology applied in cancer treatment field are mapped.
Step 2: From the perspective of applied nanotechnology, the vital role of nanotechnology applied with some anticancer treatments is explored by citation analysis.
Step 3: To link (within a network) specific nanotechnology and anticancer drugs with a specific cancer field.
Remark: Some evolutionary trends are plotted by a Log-Linear Regression model 9 , estimated by Ordinary Least Squares Method in order to approximately measure and assess, by the coefficient of regression, the acceleration of some technological trajectories. 6 Number 13, 14, 15 and 16 are not included in the figures in next section, because these keywords do not concern anticancer drugs but EGFR (epidermal growth factor receptor: the protein found on the surface of some cells and to which epidermal growth factor binds, causing the cells to divide.), HER2 (a protein involved in normal cell growth), etc. 7 For EGFR and HER2, see previous footnote. 8 Poly(lactic-co-glycolic acid) (PLGA) is one of the most successfully developed biodegradable polymers.
Among the different polymers developed to formulate polymeric nanoparticles, PLGA has attracted considerable attention due to its attractive properties (Danhier F. et al., 2012) . 9 The estimation of a linear relationship is based on the following model:
Given that not all the nanotechnologies are equally applied in all cancer treatments, we adopt network analysis to link and detect the specific nanotechnology and anticancer drugs/therapies to cancer field.
Step 4: To spot the top profile countries which are in the leading position in applying new cancer treatments by nanotechnology.
Moreover if we suppose i is a certain country and j is the cancer field, the research weight of country i in field j can be calculated by i-country's publications in j-field divided by all global publications in j-field. Hence, the general research weight index ( ) of i-country is the sum of i-country's research weight in all cancer fields. This is given by:
Step 5: To examine the internal specification of each top country.
Each country may have their own concentration of research in nanotechnology applied to treat specific types of cancer. Therefore, we use the following index to examine country's specialization in the seven cancer treatment areas. Specialization ratio of country i in field j, defined as , is the ratio of its publications in j field divided by its total publications in all cancer fields. Specialization ratio of worldwide in j field, written as , is the ratio of worldwide publications in j field divided by total publication in all cancer fields worldwide. The disparity between and is the specialization index of country i in field j, which is taken as γ .
; 1, … , .
A high level of index γ indicates that the high specialization of the country i in the specific research field j.
In particular, γ0 means high specialization in the scientific research in this type of cancer, whereas if γ  0 means that there is lower specialization. High values γ means a higher intensive research activity in the specific cancer area by application of nanotechnology to cancer treatments.
In addition, this study intends to test the following hypothesis (HP) by a hypotheticaldeductive approach proposed by Carl Hempel:
HP: High growth of trajectories of nanotechnology applied to new anticancer treatments is due to higher rate of mortality of some types of cancer.
In order to validate this HP, a main statistical technique applied is the nonparametric measure of association by the coefficients of correlation Tau-b of Kendall and of Spearman between average nanocitations and ratio mortality/incidence. This research departs from the position that there can be no adequate knowledge where causes are unknown and analyses the phenomena to be explained by a scientific realism. Figure 1 shows that the number of scientific publications concerning cancer treatments associated to nanotechnology is growing over years. The highest magnitude of scientific output in these research fields is driven by cancers that have a high incidence rate, such as breast, lung and colon cancer. In addition, it is interesting to note that growth rate of scientific research by brain and pancreatic cancer is increased sharply in later years, although they had a low activity of scientific production in early 2000. In fact, coefficient of regression (a proxy of increase over time) by brain and pancreatic cancer trends is higher than Breast cancer. In the long run, there shows a convergence of these trajectories over time. This general trend can be further approved by the citation of nanotechnology in these fields (see Figure 1A in Appendix). Source: Authors' own calculation.
Experimental results and discussions
To take the size of different research fields into account, we calculate the average of nano citation intensity concerning nano applications in the studied seven cancer fields. In particular, Table 1 shows that nanotechnology applications have the highest citation intensity in brain cancer. Following brain cancer, pancreatic cancer is the second field where nanotechnology has been intensively applied to new anticancer treatments, with average nanocitation intensity at 11.9%. Albeit the total research output of nanotechnology in breast cancer, colon cancer and prostate cancer, as showed in Figure 1 , is rather high, the citation intensity of nanotechnology in these three cancer fields is relatively low (see the last three rows of the first column in Table 1 ). 1) The percentage of nano citation is standardized. Namely, the citation intensity is calculated by the citation of nano in that year divided by the total publications of that cancer field in all previous years. 2) Due to the lack of citation data for some small research fields in early years, the average is taken between 2009 and 2012. Source: Authors' own calculation.
In order to test the HP, Table 1 shows the combination of factors of the mortality and incidence rate of different cancer fields. It is interesting to observe that cancer fields in which the ratio of mortality to incidence (Called RaMI) is high, all have high nano citation density, and vice versa. In fact, coefficients of correlation between average nanocitations and ratio RaMI are: Tau-b of Kendall= +0.59; Spearman =+0.76 (sig. 0.05). This result suggests that cancer fields, where incidence is low while mortality is high, although the total joint research output with nanotechnology is relatively low, the intensity of nanotechnology applications to ground-breaking anticancer treatments is very high. This reveals that nanotechnology plays a crucial role in these specific cancers (with high mortality rate) because it might support new technological avenues to find effective therapies in order to increase the survival of patients. Figure 2 , where the high intensive citations of nanotechnology research are exactly in brain and pancreatic cancer (cf. also the Figure 1A ). The high growth of these anticancer drugs can be due to broad spectrum of applications to treat different cancer: Doxorubicin is commonly used to treat some leukemias and Hodgkin's lymphoma, as well as cancers of the bladder, breast, stomach, lung, ovaries, thyroid, soft tissue sarcoma, multiple myeloma, and others. Instead, paclitaxel albumin-stabilized nanoparticle formulation is a form of paclitaxel contained in nanoparticles (very tiny particles of protein). This form seems to work better than other forms of paclitaxel and has fewer side effects. National Cancer Institute (2013) states that paclitaxel albumin-stabilized nanoparticle formulation is approved to be used alone or with other drugs to treat: • Breast cancer that has recurred (come back) or metastasized (spread to other parts of the body).
This result validates the HP and is confirmed by
• Non-small cell lung cancer that is locally advanced or has metastasized and cannot be treated with surgery or radiation therapy. It is used with carboplatin.
• Pancreatic cancer that has metastasized. It is used with gemcitabine hydrochloride. has generating a revolution in clinical practice (Coccia, 2012b) . Figure 3 shows growing trends of the association between target/anti-oestrogen therapy and nanotechnology are by cetuximab and tamoxifen. Cetuximab is a monoclonal antibody 10 that is approved to treat some patients with squamous cell carcinoma of the head and neck or colorectal cancer.
Tamoxifen is a type of anti-oestrogen, a drug used to treat certain types of breast cancer and to prevent breast cancer. It blocks the effects of the hormone oestrogen in the breast.
Tamoxifen is also being studied in the treatment of other types of cancer. Herceptin 10 "A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. There are many kinds of monoclonal antibodies. A monoclonal antibody is made so that it binds to only one substance. Monoclonal antibodies are being used to treat some types of cancer. They can be used alone or to carry drugs, toxins, or radioactive substances directly to cancer cells" (National Cancer Institute, 2013) .
anticancer treatments by nanotechnology: The first cluster is doxorubicin and paclitaxel applied by nanotechnology (see the high number and larger thickness of arrows): these chemotherapy agents have a broad-spectrum of action (based on high number of citations) on different types of cancers. As a matter of fact, doxorubicin has a strong connection with brain cancer, whereas paclitaxel has a strong association meanly with brain, ovarian, breast and lung cancer.
The second cluster is given by other nanotechnology-based chemotherapy agents, which have a reduced spectrum of applications, more focused on specific cancers, such as:
gemcitabine for pancreatic and brain cancer (the nanotechnology based gemcitabine agents also plays a main role to treat metastases of brain cancer), cisplatin for ovarian cancer, docetaxel for brain and ovarian cancer. Figure 4 also shows that breast and lung cancer have a large volume of research records in this field concerning new treatments with nanotechnology (larger square), whereas nanotechnology associated to doxorubicin and paclitaxel is those more frequently cited. Similarly to the previous results, Figure 5 presents also two groups of anticancer treatments based on nanotechnology, i.e. widely applied general molecular target therapy/substance with nanotechnology and specifically applied one. The curcumin substance for chemoprevention and cancer siRNA therapy applied by nanotechnology have a broad spectrum of applications on several types of cancer (curcumin has a strong connection mainly with brain, colon and prostate cancer-based on high citations-; siRNA with pancreatic cancer; cf. Yang et al., 2012) .
Herceptin via nanotechnology is applied mainly on breast cancer, cetuximab on brain cancer and lapatinib 11 for breast and pancreatic cancer. Figure 5 also shows an interesting connection between tamoxifen via nanotechnology and brain cancer. Tamoxifen is most often used to treat or prevent breast cancer, however it has also been tried for other cancers, including brain tumours, however tamoxifen trial to treat brain cancer show that the effectiveness of this anticancer treatment has high uncertainty. As well as, an interesting connection is between lapatinib via nanotechnology and pancreatic cancer. In fact, based on in vitro results, lapatinib may provide clinical benefit in EGFR 12 positive pancreatic ductal adenocarcinoma .
11 Lapatinib is approved for the treatment of certain types of advanced or metastatic breast cancer. 12 Epidermal growth factor receptor, cf. Coccia (2012b) brain, lung and colon cancer have a larger volume of research records in these fields (larger square). Source: Authors' own calculation.
To explore the sources of the scientific research on ground-breaking applications of anticancer drugs via nanotechnology, we spot the top 15 performer countries in Figure 6 .
These high performer countries are mainly (in decreasing order with standardized value):
USA, China, Italy, Japan, India, Germany and UK. These are also the countries with a high intensity of scientific research of anticancer drugs by nanotechnology in all specific types of cancer. However, Motoyama and Eisler (2013) argue that when academic publications are divided by number of researcher, the USA is not the leader but lags behind the Germany and the United Kingdom. Table 1A in the Appendix. Source: Authors' own calculation.
Lessons learned and concluding observations
Chemotherapy has non-specific effects in the body on normal tissues, causes toxicity, reduces the quality of life of patients, weakens the immune system and can damage in irreversible way the recovery power of patients. Instead, according to Gao et al. (2013) :
"nanotechnology-based chemotherapies seem to have an ability to specifically and safely reach tumor foci with enhanced efficacy and low toxicity". In particular, nanotechnology tends to support the discovery and clinical development of novel therapies for oncology focused on chemotherapy agents, small molecule and protein drugs (target therapy).
Nanotechnology is contributing to create differentiated products and enhance clinical practice for new anticancer treatments (cf. Bertrand et al., 2013) . This ground-breaking pattern of nanotechnology in medicine is enhanced by the mechanism of "'learning via diffusion' ….
The increased adoption of a technology paves the way for improvement in its characteristics" (Sahal as quoted by Coccia, 2014 ).
The present paper analyses the new trajectories of ground-breaking cancer treatments based on nanotechnology. Using publication and citation data, covering seven cancer fields and several types of anticancer treatments via nanotechnologies, our study shows here that some emerging directions of nanoscience and nanotechnology in oncology are growing rapidly over time.
Some main findings of this study are:
 Technological waves. The first main finding, over the studied 13 years, is represented by two main technological waves concerning the application of anticancer treatments by nanotechnology (Fig. 3) Hence, new nanotechnological avenues are paving a pervasive diffusion in biomedical sciences and generating a revolution in clinical practice to treat (and we hope to cure) cancers in order to lead to longer, better and healthier living of societies in a not-too-distant future (Mangematin and Walsh, 2012) .
However, emerging trajectories of nanoscience and nanotechnology are also problematic in medicine because they have several and unpredictable directions, in particular when we know that in the life science systems other things are often not equal and can change in the presence of turbulent and fast-running technological change.
13 Cf. Motoyama et al. (2014) . Note: if i is the country and j is the research field (e.g. Breast cancer), the location of the countries in the map is given by the index γ that indicates the high specialization of the country i in the specific research field j ; ; ; 1, … , .
In Bold the countries with the highest value γ; moreover, if the index γ0 means high specialization in the scientific research in this type of cancer, whereas if γ  0 means that there is lower specialization. High values γ means a higher intensive research activity in the specific cancer area.
Source: Authors' own calculation.
